- Home
- KOS vs RGNX Comparison
KOS vs RGNX Comparison
Compare KOS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- RGNX
- Stock Information
- Founded
- KOS 2003
- RGNX 2008
- Country
- KOS United States
- RGNX United States
- Employees
- KOS N/A
- RGNX N/A
- Industry
- KOS Oil & Gas Production
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOS Energy
- RGNX Health Care
- Exchange
- KOS Nasdaq
- RGNX Nasdaq
- Market Cap
- KOS 698.3M
- RGNX 661.2M
- IPO Year
- KOS 2011
- RGNX 2015
- Fundamental
- Price
- KOS $1.67
- RGNX $13.13
- Analyst Decision
- KOS Hold
- RGNX Strong Buy
- Analyst Count
- KOS 5
- RGNX 7
- Target Price
- KOS $3.40
- RGNX $30.00
- AVG Volume (30 Days)
- KOS 10.0M
- RGNX 650.0K
- Earning Date
- KOS 11-03-2025
- RGNX 11-04-2025
- Dividend Yield
- KOS N/A
- RGNX N/A
- EPS Growth
- KOS N/A
- RGNX N/A
- EPS
- KOS N/A
- RGNX N/A
- Revenue
- KOS $1,488,836,000.00
- RGNX $155,782,000.00
- Revenue This Year
- KOS N/A
- RGNX $203.79
- Revenue Next Year
- KOS $15.84
- RGNX $0.72
- P/E Ratio
- KOS N/A
- RGNX N/A
- Revenue Growth
- KOS N/A
- RGNX 74.95
- 52 Week Low
- KOS $1.39
- RGNX $5.04
- 52 Week High
- KOS $4.22
- RGNX $13.39
- Technical
- Relative Strength Index (RSI)
- KOS 52.21
- RGNX 64.26
- Support Level
- KOS $1.41
- RGNX $12.06
- Resistance Level
- KOS $1.51
- RGNX $13.39
- Average True Range (ATR)
- KOS 0.09
- RGNX 0.85
- MACD
- KOS 0.00
- RGNX 0.09
- Stochastic Oscillator
- KOS 56.67
- RGNX 91.43
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.